From Waterloo to the Great Wall: A retrospective, multicenter study on the clinical practice and cultural attitudes in the management of premature ejaculation, in China
Andrology · 2024
DOI: 10.1111/andr.13403 ↗At a glance
Multizentrische Studie in Andrology, 2024. Written by Andrea Sansone and 27 co-authors. Institution: Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Major MEDLINE topics: Premature Ejaculation, Naphthalenes. Cited 23 times so far (Crossref); 90 references. The full text is freely available (open access, CC BY 4.0). Funded by: PRIN grant, Italian Ministry of Education, University and Research, National Natural Science Foundation of China.
Abstract (original language)
Premature ejaculation (PE), despite its wide prevalence, is largely underdiagnosed and undertreated. Being a multifactorial dysfunction with strong cultural characteristics, PE requires skillful attitudes in the psychosexological support, necessary to manage the patient's and the couple's expectations, as well as in the medical treatment. Dapoxetine is a short‐acting selective serotonin reuptake inhibitor approved for use in lifelong and acquired PE in a number of countries. Opinions, not always generated by the evidence‐based medicine, impacted the attitudes of Western andrologists, as a nocebo effect which produced a drug's Waterloo, characterized by low prescription rates much more built on the patients’ and doctors’ expectations than on costs, side effects, and efficacy. In the present study, we retrospectively reviewed real‐life data from eight Andrology and Sexual Medicine Public Centers in China to assess the prevalence of PE among attending patients, its association with erectile dysfunction, its subtype, and the proposed treatments. In 2019, among 156,486 patients coming to the centers, 32,667 visits having PE as the chief complaint were performed (20.9%). Almost all patients received treatment prescriptions (32,641 patients, 99.92%); 23,273 patients came back for a follow‐up visit in the subsequent 12 months (71.2% of those who initially received treatment). Dapoxetine, either alone or in combination with another therapy, was the most prevalent treatment, prescribed to 22,767 patients (69.7% of treated patients), followed by traditional Chinese medicine (TCM) (39.4%). At follow‐up, 8174 patients were unsatisfied with treatment, and a new treatment was proposed (35.12%). Dapoxetine was the best treatment, with an overall 27.1% switching rate when used either alone or in combination: Although the switching rate for Dapoxetine alone was 44.2%, the association of the same drug with psychotherapy resulted in much lower rates (19.5%) and reached a minimum of 12% when also combined with TCM demonstrating how cultural aspects and medical attitudes may dramatically impact on the therapy of a multifaceted, complex, and culture‐grounded sexual symptom such as PE. In conclusion, taking switching rates as surrogate markers of treatment failure, this real‐life study—the largest in the field—shows that in a more patient‐oriented (as in Chinese medical culture), and less symptom‐oriented (as in Western medical attitudes), Dapoxetine is a successful treatment for PE patients, with higher reliability when used alone or as part of combined and integrated therapies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- Department of Andrology, Xi'an Daxing Hospital, Xi'an, China.
- Peking University 3rd Hospital, Beijing, China.
- Peking University 1st Hospital, Beijing, China.
- Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
ORCID profiles: Andrea Sansone, Jianlin Yuan, Guangdong Hou, Lei Zhang, Ming Gao, Zhe Zhang, Hui Jiang, Ming Wang, Xiansheng Zhang, Xi Yu, Yong-Gang Duan, Emmanuele A Jannini, Elena Colonnello, Daniele Mollaioli, Xinlong Dun, Haocheng Lin
Funding
- PRIN grant
- Italian Ministry of Education, University and Research
- National Natural Science Foundation of China
- Youth Fund Project of National Natural Science Foundation of China
- Young science and technology stars in Shaanxi Province
- International Science and Technology Cooperation Program of Shaanxi Province
- General Project
- General projects of Shaanxi Provincial Health Commission
Cite
APA
Sansone, A., Yuan, J., Hou, G., Zhang, L., Gao, M., Zhang, Z., Jiang, H., Wang, F., Guo, J., Geng, Q., Wang, M., Zhang, X., Yu, X., Zhang, Y., Liu, J. C., Duan, Y. G., Nagrale, D., Chen, Z., Jannini, E. A., …, & Zhang, H. (2024). From Waterloo to the Great Wall: A retrospective, multicenter study on the clinical practice and cultural attitudes in the management of premature ejaculation, in China. Andrology. https://doi.org/10.1111/andr.13403
Vancouver
Sansone A, Yuan J, Hou G, Zhang L, Gao M, Zhang Z, et al. From Waterloo to the Great Wall: A retrospective, multicenter study on the clinical practice and cultural attitudes in the management of premature ejaculation, in China. Andrology. 2024. doi:10.1111/andr.13403
BibTeX
@article{Sansone2024,
author = {Sansone, Andrea and Yuan, Jianlin and Hou, Guangdong and Zhang, Lei and Gao, Ming and Zhang, Zhe and Jiang, Hui and Wang, Fu and Guo, Jun and Geng, Qiang and Wang, Ming and Zhang, Xiansheng and Yu, Xi and Zhang, Yan and Liu, Jin-Chuan and Duan, Yong-Gang and Nagrale, Dinesh and Chen, Zhiguo and Jannini, Emmanuele A and MAPS-GOSH (Marco Polo Study Group on Sexual Health) Other MAPS-GOSH members, MAPS-GOSH (Marco Polo Study Group on Sexual Health) Other MAPS-GOSH members and Colonnello, Elena and Ciocca, Giacomo and Limoncin, Erika and Mollaioli, Daniele and Dun, Xinlong and Yuan, Jiarui and Lin, Haocheng and Zhang, Hui},
title = {From Waterloo to the Great Wall: A retrospective, multicenter study on the clinical practice and cultural attitudes in the management of premature ejaculation, in China},
journal = {Andrology},
year = {2024},
doi = {10.1111/andr.13403}
}
EUVIMED